期刊文献+

甲状腺乳头状微小癌中survivin、galectin-3、TPO蛋白表达与BRAF^(V600E)基因突变关系的研究 被引量:9

Study on relationship between expression of survivin,galectin-3 and TPO and BRAF^(V600E) mutation in patients with papillary thyroid microcarcinoma and its clinical significance
在线阅读 下载PDF
导出
摘要 目的:检测甲状腺乳头状微小癌(PTMC)及其癌旁良性组织中细胞凋亡抑制因子存活素(survivin)、半乳糖凝集素-3(Gal-3)和甲状腺髓过氧化物酶(TPO)蛋白表达差异以及PTMC中鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)基因的突变,探讨survivin、Gal-3和TPO蛋白与BRAFV600E基因突变的关系。方法:采用免疫组织化学方法检测56例PTMC组织及其癌旁良性组织中survivin、Gal-3和TPO蛋白的表达情况;对聚合酶链式反应(PCR)扩增产物直接测序,分析BRAFV600E基因突变情况;survivin、Gal-3和TPO蛋白表达阳性率与BRAF基因突变率关系分析采用χ2检验方法。结果:PTMC癌组织中,survivin和Gal-3强阳性表达,而TPO不表达;癌旁良性组织中,survivin和Gal-3表达缺失,TPO正常表达;survivin、Gal-3和TPO在癌组织和其癌旁良性组织间的表达率比较差异均有统计学意义(均P<0.001);BRAFV600E基因在PTMC中有32.1%(18/56)突变;BRAFV600E基因突变率和3种蛋白在PTMC组织中的表达率与淋巴结转移有关联(P=0.009,P=0.025,P=0.007,P=0.008),而与患者年龄和性别无关联(均P>0.05);BRAFV600E基因突变与survivin、Gal-3、TPO蛋白表达均无关联(均P>0.05)。结论:PTMC癌组织中,survivin和Gal-3表达升高、TPO表达降低和BRAFV600E基因突变可能在PTMC发生发展中起重要作用,survivin、Gal-3、TPO蛋白表达与BRAFV600E基因突变的检测,可为PTMC病情的判定、预后的转归提供有价值的信息。 Objective: To detect the expressions of survivin, galectin-3 and thyroid peroxidase in papillary thyroid microcarcinoma (PTMC) and cancer adjacent normal tissue to explore the clinical significant. The correlations between the expressions of survivin,Gal-3 and TPO with BRAF^V600E gene mutation in PTMC were analyzed. Methods: The expressions of survivin, Gal-3 and TPO were measured by immunohistoehemical ( IHC ) method in 56 cases of PTMC tissue and adjacent normal tissue ; BRAF^V600Emutation was detected by PCR amplification and subsequently sequencing. Chi square test was used to analyse the relation in the expression rates of survivin, Gal-3 and TPO and BRAF^V600E gene mutation. Results : The survivin and Gal-3 were strongly expressed but TPO was negatively expressed. The survivin and Gal-3 were negative in adjacent normal tissues but TPO was expressed. There were sig- nificant differences in the expression rates of survivin, Gal-3 and TPO between PTMC tissue and adjacent normal tissue (all P〈0. 001). The BRAF^V600E mutation rate (32. 1% ) and the expression rates of survivin, Gal-3 and TPO in PTMC tissue were found to be positively related to lymph node metastases (P = 0. 009, P = 0. 025, P = 0. 007, P = O. 008 ), and negatively related to gender and age ( all P〉0.05 ). There were no correlation was found between the expressions of survivin, Gal-3, TPO and the BRAF^V600E gene mutation in PTMC ( all P〉0.05 ). Conclusion: The strong expressions of survivin and Gal-3, the mild expression of TPO and BRAF mutation may be important in the development of PTMC, and the detection of BRAF^V600E gene mutation and the expressions of survivin,Gal-3 and TPO could be used to the judgment of pathogenetic condition and prognostic outcomes.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第11期1462-1466,共5页 Chinese Journal of Immunology
基金 吉林省科技厅科技发展计划项目(20120733) 长春市科技发展计划项目(2012130-12SF58)资助
关键词 甲状腺乳头状微小癌 细胞凋亡抑制因子 半乳糖凝集素-3 甲状腺髓过氧化物酶 BRAF基因突变 Papillary thyroid microcarcinoma survivin Galectin-3 Thyroid peroxidase BRAF mutation
  • 相关文献

参考文献15

  • 1Zheng X,Wei S,Han Y,et al.Papillary microcarcinoma of thethyroid:clinical characteristics and BRAF(V600E)mutationalstatus of 977 cases[J].Ann Surg Oncol,2013,20(7):2266-2273.
  • 2Wu LS,Milan SA.Management of microcarcinomas(papillary andmedullary)of the thyroid[J].Curr Opin Oncol,2013,25(1):27-32.
  • 3Li X,Abdel-Mageed AB,Kandil E.BRAF mutation in papillarythyroid carcinoma[J].Int J Clin Exp Med,2012,5(4):310-315.
  • 4Kim YA5Chang M,Park YJ,et al.Detection of survivin and COX-2in thyroid carcinoma:anaplastic carcinoma shows overexpression ofnuclear survivin and low COX-2 expression[J],Korean J Pathol,2012,46(1):55-60.
  • 5Makki FM,Taylor SM,Shahnavaz A,et al.Serum biomarkers ofpapillary thyroid cancer[J].J Otolaryngol Head and Neck Surg,2013,42(1):16-25.
  • 6Yousaf U,Christensen LH,Rasmussen AK,et al.mmunohistoch-emical staining for thyroid peroxidase(TPO)of needle corebiopsies in the diagnosis of scintigraphically cold thyroid nodules[J].Clin Endocrinol,2008,68(6):996-1001.
  • 7Virk RK,Van Dyke AL,Finkelstein A,et al.BRAFv600e mutationin papillary thyroid microcarcinoma:a genotype-phenotypecorrelation[J].Mod Pathol,2013,26(1):62-70.
  • 8Rossi ED,Martini M,Capodimonti S,et al.BRAF(V600E)mutation analysis on liquid-based cytology-processed aspirationbiopsies predicts bilaterality and lymph node involvement inpapillary thyroid microcarcinoma[J].Cancer Cytopathol,2013,121(6):291-297.
  • 9Antonaci A,Consorti F,Mardente S,et al.Survivin and cyclin Dlare jointly expressed in thyroid papillary carcinoma andmicrocarcinoma[J].Oncol Rep,2008,20(1):63-67.
  • 10Liu YY, Morreau H, Kievit J, et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-tgammal, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma [ J]. Eur J Endocrinol.2008.158 (3) :375-384.

同被引文献114

引证文献9

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部